3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Cyclophosphamide
10
fludarabine phosphate
9
Rituximab
9
Cytarabine
9
Peripheral Blood Stem Cell Transplantation
8
Methotrexate
8
Filgrastim
6
Cyclosporine
6
fludarabine
5
Radiotherapy
5
Busulfan
5
Tacrolimus
4
Mycophenolic Acid
4
Idarubicin
4
Granulocyte Colony-Stimulating Factor
4
Bendamustine Hydrochloride
4
venetoclax
3
duvelisib
3
Whole-Body Irradiation
3
Sirolimus
3
Melphalan
3
Antilymphocyte Serum
3
Prednisone
2
N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine
2
Mitoxantrone
2
Lenalidomide
2
Interferon-alpha
2
Drug Therapy
2
Clofarabine
2
Arsenic Trioxide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Leukemia
×
navitoclax
×
Clear all
NCT05740449
2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2
Withdrawn